A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
Latest Information Update: 19 Nov 2019
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jan 2013 New trial record